Shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus target price of $13.50 for the company, according to Zacks. Zacks has also given Valeritas an industry rank of 187 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine upgraded Valeritas from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

Valeritas (NASDAQ VLRX) traded up $0.08 during midday trading on Wednesday, hitting $2.98. The company had a trading volume of 1,170 shares, compared to its average volume of 9,453. The company has a quick ratio of 2.40, a current ratio of 3.02 and a debt-to-equity ratio of -8.88. Valeritas has a one year low of $2.00 and a one year high of $25.54. The company has a market capitalization of $21.09, a price-to-earnings ratio of -0.22 and a beta of 4.91.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

Valeritas Company Profile

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with's FREE daily email newsletter.